Hearing Monitoring Frequency for ARIKAYCE
Patients receiving ARIKAYCE should have baseline audiometry performed before treatment initiation, followed by close monitoring for auditory symptoms throughout therapy, with formal audiometric testing repeated if any symptoms of ototoxicity develop.
Baseline Assessment
Before starting ARIKAYCE, obtain comprehensive baseline auditory evaluation including 1:
- Complete audiogram (conventional and ideally high-frequency testing)
- Assessment for any pre-existing auditory dysfunction
- Evaluation for mitochondrial DNA variants (MT-RNR1, particularly m.1555A>G) if family history of aminoglycoside-related hearing loss exists
Ongoing Monitoring During Treatment
Clinical Surveillance
Monthly assessments should include 1:
- Questioning patients specifically about auditory symptoms (tinnitus, hearing changes, dizziness)
- Assessment for vestibular symptoms (unsteady gait, vertigo, presyncope)
The FDA label for ARIKAYCE emphasizes "closely monitor patients with known or suspected auditory or vestibular dysfunction during treatment" but does not mandate specific intervals for formal audiometry in asymptomatic patients 1.
Symptom-Triggered Audiometry
Formal audiometric testing should be repeated immediately if 1:
- Tinnitus develops (occurred in 8.1% of ARIKAYCE patients vs 0.9% in controls)
- Any hearing changes are reported
- Dizziness or vestibular symptoms emerge (6.3% vs 2.7% in controls)
- Any signs of ototoxicity appear
Key Differences from Parenteral Aminoglycosides
This monitoring approach differs significantly from parenteral (IV/IM) aminoglycosides, where guidelines recommend more structured serial audiometry 2, 3, 2:
- Parenteral amikacin/streptomycin: Baseline audiogram, vestibular testing, and Romberg testing required, with monthly renal function assessments and questioning about auditory/vestibular symptoms; repeat audiogram and vestibular testing if symptoms develop
- ARIKAYCE (inhaled): Lower systemic exposure results in reduced ototoxicity risk compared to IV formulations, though monitoring remains essential
High-Frequency Audiometry Considerations
While not specifically required by the ARIKAYCE label, research demonstrates that high-frequency audiometry (9-20 kHz) detects aminoglycoside ototoxicity earlier than conventional testing 4, 5, 6:
- High-frequency hearing loss appears first in 62.5-71% of cases
- Conventional frequencies alone miss early changes in 13.5% of patients
- Consider high-frequency testing for patients at higher risk or with prolonged therapy
Special Populations Requiring Enhanced Monitoring
Intensify monitoring frequency for 1:
- Patients with pre-existing auditory or vestibular dysfunction
- Known mitochondrial DNA variants (MT-RNR1)
- Maternal history of aminoglycoside-related ototoxicity
- Concurrent use of other ototoxic medications
- Renal impairment (increases systemic aminoglycoside exposure)
Clinical Context
The ototoxicity profile of ARIKAYCE differs from parenteral aminoglycosides due to targeted pulmonary delivery 7, 8:
- Systemic exposure is substantially lower (mean Cmax 2.8 mcg/mL vs ~76 mcg/mL for IV amikacin)
- Ototoxicity occurred in 17% of ARIKAYCE patients vs 9.8% in controls, primarily driven by tinnitus and dizziness rather than permanent hearing loss
- Most auditory adverse events did not lead to discontinuation (<3% for any single symptom)
Important Caveats
Aminoglycoside ototoxicity is typically irreversible 9. Therefore:
- Patient education about early symptoms is critical
- Low threshold for formal audiometric evaluation when symptoms emerge
- Consider discontinuation or dose modification if ototoxicity develops
- The risk-benefit calculation may favor discontinuation given the irreversible nature of hearing loss
The less rigid monitoring schedule for ARIKAYCE compared to parenteral aminoglycosides reflects its improved safety profile, but vigilance remains essential given the potential for permanent auditory damage 1.